Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: A preliminary report

Blood Purification

Volumn 38, Issue 3-4, 2014, Pages 211-218

  Shiga, Hidetoshi ^a   Hirasawa, Hiroyuki ^b   Nishida, Osamu ^c   Oda, Shigeto ^b   Nakamura, Masataka ^b   Mashiko, Kunihiro ^d   Matsuda, Kenich ^e   Kitamura, Nobuya ^f   Kikuchi, Yoshihiko ^a   Fuke, Nobuo ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f KIMITSU CHUO HOSPITAL   (Japan)

Author keywords

AN69ST hemofilter; Continuous hemodiafiltration; Cytokine adsorbing hemofilter; Hypercytokinemia; Septic shock; Surviving Sepsis Campaign guidelines

Indexed keywords

ACRYLONITRILE METHALLYL SULFONATE COPOLYMER; COPOLYMER; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACRYLIC ACID RESIN; ACRYLONITRILE; AN-69; ARTIFICIAL MEMBRANE; CATECHOLAMINE; CYTOKINE; IL6 PROTEIN, HUMAN; LACTIC ACID DERIVATIVE;

AGED; APACHE; ARTICLE; BLOOD FILTER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; CYTOKINE ADSORBING HEMOFILTER; CYTOKINE STORM; FEMALE; HUMAN; LACTATE BLOOD LEVEL; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ARTIFICIAL MEMBRANE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DEVICES; HEMODIAFILTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROCEDURES; SHOCK, SEPTIC; VERY ELDERLY;

ACRYLIC RESINS; ACRYLONITRILE; AGED; AGED, 80 AND OVER; APACHE; BLOOD PRESSURE; CATECHOLAMINES; CYTOKINES; FEMALE; HEMODIAFILTRATION; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LACTATES; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84920023263     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000369377     Document Type: Article

References (30)

1. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013; 381: 774-775.
2. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 289-296.
3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
4. Rimmele T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care 2011; 15: 205.
5. Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, Hirasawa H. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 2008; 14: 257-263.
6. Thomas M, Moriyama K, Ledebo I. AN69: evolution of the world's first high permeability membrane. Contrib Nephrol 2011; 173: 119-129.
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
8. Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD, Manthous C, Meduri GU, Moreno RP, Putensen C, Stewart T, Torres A. Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med 2007; 33: 575-590.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
10. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-2452.
11. Hirasawa H, Oda S, Nakamura M, Watanabe E, Shiga H, Matsuda K. Continuous hemodiafiltration with a cytokine-Adsorbing hemofilter for sepsis. Blood Purif 2012; 34: 164-170.
12. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309: 1154-1162.
13. Shapiro NI, Howell MD, Talmor D, Lahey D, Ngo L, Buras J, Wolfe RE, Weiss JW, Lisbon A. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med 2006; 34: 1025-1032.
14. Shorr AF, Micek ST, Jackson WL Jr, Kollef MH. Economic implications of an evidencebased sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med 2007;35: 1257-1262.
15. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008;299: 2294-2303.
16. Castellanos-Ortega A, Suberviola B, Garcia-Astudillo LA, Holanda MS, Ortiz F, Llorca J, Delgado-Rodriguez M. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasi-experimental study. Crit Care Med 2010;38: 1036-1043.
17. Miller RR 3rd, Dong L, Nelson NC, Brown SM, Kuttler KG, Probst DR, Allen TL, Clemmer TP; Intermountain Healthcare Intensive Medicine Clinical Program: Multicenter implementation of a severe sepsis and septic shock treatment bundle. Am J Respir Crit Care Med 2013; 188: 77-82.
18. Angus DC. The search for effective therapy for sepsis: back to the drawing board?. JAMA 2011; 306: 2614-2615.
19. Tse MT. Trial watch: sepsis study failure highlights need for trial design rethink. Nat Rev Drug Discov 2013; 12: 334.
20. Iwagami M, Yasunaga H, Doi K, Horiguchi H, Fushimi K, Matsubara T, Yahagi N, Noiri E. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med 2014; 42: 1187-1193.
21. Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J; LACTATE study group: Early lactate-guided therapy in intensive care unit patients: a multicenter, openlabel, randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 752-761.
22. Levraut J, Ciebiera JP, Jambou P, Ichai C, Labib Y, Grimaud D. Effect of continuous venovenous hemofiltration with dialysis on lactate clearance in critically ill patients. Crit Care Med 1997; 25: 58-62.
23. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005; 29: 169-175.
24. Nakamura M, Oda S, Sadahiro T, Hirayama Y, Watanabe E, Tateishi Y, Nakada TA, Hirasawa H. Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contrib Nephrol 2010; 166: 73-82.
25. Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010;181: 1128-1155.
26. Joannes-Boyau O, Honore PM, Perez P, Bagshaw SM, Grand H, Canivet JL, Dewitte A, Flamens C, Pujol W, Grandoulier AS, Fleureau C, Jacobs R, Broux C, Floch H, Branchard O, Franck S, Roze H, Collin V, Boer W, Calderon J, Gauche B, Spapen HD, Janvier G, Ouattara A. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013; 39: 1535-1546.
27. Lukaszewicz AC, Payen D. Purification methods: a way to treat severe acute inflammation related to sepsis?. Crit Care 2013; 17: 159.
28. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 2010; 363: 689-691.
29. Nakamura M, Oda S, Sadahiro T, Watanabe E, Abe R, Nakada TA, Morita Y, Hirasawa H. Correlation between high blood IL-6 level, hyperglycemia, and glucose control in septic patients. Crit Care 2012; 16:R58.
30. Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med 2010; 38:S534-S538.